Cargando…

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions

BACKGROUND: We tested the hypothesis that BRCA1/2 mutation carriers with ovarian cancer are at higher risk of carboplatin hypersensitivity reactions (HSRs). METHODS: Medical records of women enrolled in two carboplatin+olaparib clinical trials (NCT01237067/NCT01445418) were reviewed. A maximum of ei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moon, D H, Lee, J-M, Noonan, A M, Annunziata, C M, Minasian, L, Houston, N, Hays, J L, Kohn, E C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749564/ https://www.ncbi.nlm.nih.gov/pubmed/23867999 http://dx.doi.org/10.1038/bjc.2013.389

Ejemplares similares

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
por: Osorio, A, et al.
Publicado: (2011)

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
por: Osorio, A, et al.
Publicado: (2009)

Carboplatin-Induced Hypersensitivity Reaction
por: Potolidis, Evangelos, et al.
Publicado: (2012)

Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
por: Phelan, C M, et al.
Publicado: (2014)

Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ‘easy to apply’ probability models
por: Bodmer, D, et al.
Publicado: (2006)

DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas
por: Kamieniak, M M, et al.
Publicado: (2013)

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Sinilnikova, O M, et al.
Publicado: (2009)

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
por: Lampert, Erika J., et al.
Publicado: (2019)

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
por: Mitra, A, et al.
Publicado: (2008)

Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease
por: Leongamornlert, D, et al.
Publicado: (2014)

An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers
por: Osorio, A, et al.
Publicado: (2008)

A role for BRCA1 in sporadic breast cancer
por: Fraser, J A, et al.
Publicado: (2003)

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations
por: Garcia, Andrew, et al.
Publicado: (2019)

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study
por: Iqbal, Javaid, et al.
Publicado: (2016)

BRCA1 and BRCA2 mutations in Scotland and Northern Ireland
Publicado: (2003)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families
por: Claes, K, et al.
Publicado: (2004)

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer
por: Agalliu, I, et al.
Publicado: (2007)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer
por: Akbari, M R, et al.
Publicado: (2014)

Low-level constitutional mosaicism of a de novoBRCA1 gene mutation
por: Friedman, E, et al.
Publicado: (2015)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis
por: Fernández-Ramires, R, et al.
Publicado: (2009)

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation
por: Metcalfe, K A, et al.
Publicado: (2009)

Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade
por: Ding, S L, et al.
Publicado: (2004)

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
por: Kadouri, L, et al.
Publicado: (2004)

Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia
por: Scardocci, A, et al.
Publicado: (2006)

MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours
por: Tanic, M, et al.
Publicado: (2013)

BRCA2 gene mutations in families with aggregations of breast and stomach cancers
por: Jakubowska, A, et al.
Publicado: (2002)

Identification of DBC1 as a transcriptional repressor for BRCA1
por: Hiraike, H, et al.
Publicado: (2010)

CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status
por: Gudmundsdottir, K, et al.
Publicado: (2003)

Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women
por: Sidon, L, et al.
Publicado: (2012)

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
por: Robertson, L, et al.
Publicado: (2012)

Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study
por: Jakubowska, A, et al.
Publicado: (2012)

Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers
por: Kote-Jarai, Z, et al.
Publicado: (2006)

A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories
por: Ellison, Gillian, et al.
Publicado: (2017)

Multifunctional transcription factor TFII-I is an activator of BRCA1 function
por: Tanikawa, M, et al.
Publicado: (2011)

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
por: Kote-Jarai, Z, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jloi479j8df9pva29r34bduq5j